Akasha Sananda – Trademark Portfolio
Entity Type: 01
Akasha Sananda holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 4 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include TWINRAY, DIVINITY CODE, ENLIGHTENED EARTH, and DIVINE HUMAN BIOCEUTICALS. The owner is based in Carlsbad, CA.
3313 Cabo Ct.
Carlsbad, CA 92009
Showing of trademarks Trademarks
Trademark Classifications
Akasha Sananda's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Akasha Sananda have?
Akasha Sananda has 10 U.S. trademarks filed with the USPTO. Of these, 5 registered, 5 abandoned.
What trademark classes does Akasha Sananda file in?
Akasha Sananda files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 25 (Clothing), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Akasha Sananda's most well-known trademarks?
Akasha Sananda's registered trademark portfolio includes well-known marks such as TWINRAY, DIVINITY CODE, ENLIGHTENED EARTH, and DIVINE HUMAN BIOCEUTICALS. These are among 5 currently registered trademarks in the portfolio.
What is Akasha Sananda's trademark registration success rate?
Akasha Sananda has a 50% trademark registration rate, with 5 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.